Abstract
The capacity to prevent atherothrombosis has been enhanced with the following 3 advances in antiplatelet therapy: (1) the shift from clopidogrel to more potent P2Y12 antagonists, (2) the observation that less is more in terms of antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention, and (3) the finding that the combination of low-dose rivaroxaban plus aspirin is superior to aspirin alone for prevention of recurrent ischemic events in patients with stable coronary or peripheral artery disease.
Supplementary Material
The complete text of this Blood Advances Talk is available as a data supplement.
Footnotes
Download or subscribe to the Blood Advances Talk podcast at https://soundcloud.com/blood-advances.
Contribution: N.C.C and J.I.W. drafted the outline, performed the literature search, and wrote the paper.
Conflict-of-interest disclosure: N.C.C. receives personal fees from Bayer outside the submitted work. J.I.W. receives personal fees from Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Merck, Novartis, Pfizer, Ionis Pharmaceuticals, Janssen, and Portola outside the submitted work.
Correspondence: Noel C. Chan, Thrombosis & Atherosclerosis Research Institute, McMaster University, C5-116 TaARI, DBCVRI, 237 Barton St East, Hamilton, ON L8L 2X2, Canada; e-mail: noel.chan@taari.ca.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.